KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects
September 17, 2025
KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects
European Academy of Dermatology & Venereology (EADV) 2025 – Late Breaking Oral Presentation
Mahta Mortezavi, MD, Senior Medical Director, Clinical Development
Area of Focus
Immunology
Programs
STAT6 (KT-621)
Indications
Healthy Volunteers
Development Stage
Clinical Data
Share
